Hookipa Pharma Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hookipa Pharma stock.
View analyst ratings for Hookipa Pharma or view top-rated stocks.

Wall Street analysts have given Hookipa Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hookipa Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Hookipa Pharma.

Hookipa Pharma Inc (NASDAQ:HOOK) released its earnings results on Thursday, November, 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.11. The firm had revenue of $4.04 million for the quarter, compared to analyst estimates of $4.16 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 39.58% and a negative net margin of 232.00%.
View Hookipa Pharma's earnings history.

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOOK shares have increased by 27.1% and is now trading at $11.76.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 1-year price targets for Hookipa Pharma's stock. Their forecasts range from $16.00 to $25.00. On average, they anticipate Hookipa Pharma's stock price to reach $20.20 in the next year. This suggests a possible upside of 71.8% from the stock's current price.
View analysts' price targets for Hookipa Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Hookipa Pharma include Syndax Pharmaceuticals (SNDX), Humanigen (HGEN), Cara Therapeutics (CARA), Five Prime Therapeutics (FPRX), Protagonist Therapeutics (PTGX), G1 Therapeutics (GTHX), Intercept Pharmaceuticals (ICPT), Lexicon Pharmaceuticals (LXRX), Radius Health (RDUS), Dyne Therapeutics (DYN), Prothena (PRTA), Collegium Pharmaceutical (COLL), Aclaris Therapeutics (ACRS), Phibro Animal Health (PAHC) and Vectura Group (VEGPF).
View all of HOOK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Artal Group S.A. (4.35%), BlackRock Inc. (2.94%), Northern Trust Corp (0.69%), Samsara BioCapital LLC (0.59%), Monashee Investment Management LLC (0.41%) and Nuveen Asset Management LLC (0.24%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends for Hookipa Pharma.

HOOK stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, ETF Managers Group LLC, and Barclays PLC. Company insiders that have sold Hookipa Pharma company stock in the last year include Igor Matushansky, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma or view top insider-selling stocks.

HOOK stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Monashee Investment Management LLC, Engineers Gate Manager LP, JPMorgan Chase & Co., Tudor Investment Corp Et Al, BlackRock Inc., State of Wisconsin Investment Board, and Samsara BioCapital LLC. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma or or view top insider-buying stocks.

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOOK stock can currently be purchased for approximately $11.76.

Hookipa Pharma has a market capitalization of $256.97 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

Hookipa Pharma employs 56 workers across the globe.

The official website for Hookipa Pharma is www.hookipapharma.com.

Hookipa Pharma is headquartered at 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118.

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]